Log in

NYSE:SLS - Galena Biopharma Stock Price, Forecast & News

$4.09
+0.03 (+0.74 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$3.94
Now: $4.09
$4.14
50-Day Range
$0.12
MA: $3.28
$6.16
52-Week Range
$3.67
Now: $4.09
$89.50
Volume289,532 shs
Average Volume248,426 shs
Market Capitalization$19.93 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Develop biopharmaceuticals

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorHealth Technology
CUSIPN/A
WebN/A
Phone(917) 438-4353

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$19.93 million
Next Earnings Date3/27/2020 (Estimated)
OptionableNot Optionable

Receive SLS News and Ratings via Email

Sign-up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.


Galena Biopharma (NYSE:SLS) Frequently Asked Questions

What is Galena Biopharma's stock symbol?

Galena Biopharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "SLS."

When is Galena Biopharma's next earnings date?

Galena Biopharma is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for Galena Biopharma.

Has Galena Biopharma been receiving favorable news coverage?

News articles about SLS stock have trended very positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Galena Biopharma earned a news impact score of 4.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Galena Biopharma.

Who are some of Galena Biopharma's key competitors?

What other stocks do shareholders of Galena Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galena Biopharma investors own include Nabriva Therapeutics (NBRV), Novavax (NVAX), SenesTech (SNES), Allena Pharmaceuticals (ALNA), Ameri (AMRH), Aytu Bioscience (AYTU), ConforMIS (CFMS), CHF Solutions (CHFS), Crispr Therapeutics (CRSP) and Histogenics (HSGX).

Who are Galena Biopharma's key executives?

Galena Biopharma's management team includes the folowing people:
  • Angelos M. Stergiou, President, Chief Executive Officer & Director
  • Aleksey N. Krylov, Chief Financial Officer, Treasurer & Director
  • Nicholas J. Sarlis, Director, Chief Medical Officer & Senior VP
  • Barbara A. Wood, Secretary, Executive VP & General Counsel
  • Gregory M. Torre, Director, Chief Regulatory Officer & Senior VP

How do I buy shares of Galena Biopharma?

Shares of SLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Galena Biopharma's stock price today?

One share of SLS stock can currently be purchased for approximately $4.09.

How big of a company is Galena Biopharma?

Galena Biopharma has a market capitalization of $19.93 million. View Additional Information About Galena Biopharma.

How can I contact Galena Biopharma?

The company can be reached via phone at (917) 438-4353.


MarketBeat Community Rating for Galena Biopharma (NYSE SLS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  217
MarketBeat's community ratings are surveys of what our community members think about Galena Biopharma and other stocks. Vote "Outperform" if you believe SLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel